Metagenomi Inc. Common St... (MGX)
1.27
0.01 (0.79%)
At close: Apr 04, 2025, 10:19 AM
0.79% (1D)
| Bid | 0.92 |
| Market Cap | 47.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.36 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -0.96 |
| Analyst | Buy |
| Ask | 1.57 |
| Volume | 118,958 |
| Avg. Volume (20D) | 907,668 |
| Open | 1.23 |
| Previous Close | 1.26 |
| Day's Range | 1.23 - 1.30 |
| 52-Week Range | 1.24 - 10.57 |
| Beta | -0.27 |
About MGX
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and lice...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2006
Employees 202
Stock Exchange NASDAQ
Ticker Symbol MGX
Website https://www.metagenomi.co
Analyst Forecast
According to 5 analyst ratings, the average rating for MGX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 1081.10% from the latest price.
Stock ForecastsNext Earnings Release
Metagenomi Inc. Common Stock is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
11 months ago
-12.36%
Metagenomi shares are trading lower after Moderna ...
Unlock content with
Pro Subscription
